{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:16:20Z","timestamp":1781795780480,"version":"3.54.5"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1129","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The use of stereotactic body radiotherapy (SBRT) to treat ultra-central lung tumours remains more controversial than for peripheral and central tumours. Our objective was to assess toxicities, local control (LC) rate and survival data in patients with ultra-central lung tumours treated with SBRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective and monocentric study about 74 patients with an ultra-central lung tumour, consecutively treated between 2012 and 2018. Ultra-central tumours were defined as tumours whose planning target volume overlapped one of the following organs at risk (OARs): the trachea, right and left main bronchi, intermediate bronchus, lobe bronchi, oesophagus, heart.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Median follow-up was 25 months. Two patients (2.7%) showed Grade 3 toxicity. No Grade 4 or 5 toxicity was observed. 11% of patients experienced primary local relapse. LC rate was 96.7% at 1\u2009year and 87.6% at 2 years. Median progression free survival was 12 months. Median overall survival was 31 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>SBRT for ultra-central tumours remains safe and effective as long as protecting organs at risk is treatment-planning priority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge:<\/jats:title>\n                    <jats:p>The present study is one of the rare to describe exclusively ultra-central tumours through real-life observational case reports. Globally, literature analysis reveals a large heterogeneity in ultra-central lung tumours definition, prescribed dose, number of fractions. In our study, patients treated with SBRT for ultra-central lung tumours experienced few Grade 3 toxicities (2.7%) and no Grade 4 or 5 toxicities, due to the highest compliance with dose constraints to OARs. LC remained efficient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1259\/bjr.20210533","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T15:09:04Z","timestamp":1637334544000},"source":"Crossref","is-referenced-by-count":13,"title":["Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience"],"prefix":"10.1093","volume":"95","author":[{"given":"Elodie","family":"Guillaume","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, L\u00e9on B\u00e9rard Cancer Centre , Lyon , France"},{"name":"Department of Radiation Oncology, Lucien Neuwirth Cancer Centre , Saint-Priest-en-Jarez , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Tanguy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, L\u00e9on B\u00e9rard Cancer Centre , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Ayadi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, L\u00e9on B\u00e9rard Cancer Centre , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Claude","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, L\u00e9on B\u00e9rard Cancer Centre , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Sotton","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Lucien Neuwirth Cancer Centre , Saint-Priest-en-Jarez , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Moncharmont","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, L\u00e9on B\u00e9rard Cancer Centre , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Magn\u00e9","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Lucien Neuwirth Cancer Centre , Saint-Priest-en-Jarez , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Martel-Lafay","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, L\u00e9on B\u00e9rard Cancer Centre , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"issue":"no 5","key":"2024050310481576800_b1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"2024050310481576800_b2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3747\/co.24.3358","article-title":"Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer","volume":"24","author":"Falkson","year":"2017","journal-title":"Curr Oncol"},{"key":"2024050310481576800_b3","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"2024050310481576800_b4","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jtho.2017.05.015","article-title":"Long-Term outcome of surgery or stereotactic radiotherapy for lung Oligometastases","volume":"12","author":"Lodeweges","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024050310481576800_b5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2017.05.012","article-title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer","volume":"124","author":"Guckenberger","year":"2017","journal-title":"Radiother Oncol"},{"key":"2024050310481576800_b6","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"2024050310481576800_b7","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a Five-Fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024050310481576800_b8","doi-asserted-by":"crossref","first-page":"S1066","DOI":"10.1016\/j.jtho.2016.11.1491","article-title":"P2.05-056 safety of stereotactic body radiotherapy for central, ultracentral, and paramediastinal lung tumors","volume":"12","author":"Daly","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"2024050310481576800_b9","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1111\/cas.14185","article-title":"Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer","volume":"110","author":"Meng","year":"2019","journal-title":"Cancer Sci"},{"key":"2024050310481576800_b10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"2024050310481576800_b11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with \"Ultracentral\" Non-Small Cell Lung Cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2024050310481576800_b12","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1016\/j.cllc.2018.06.001","article-title":"Ultracentral tumors treated with stereotactic body radiotherapy: single-institution experience","volume":"19","author":"Raman","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2024050310481576800_b13","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-018-1001-6","article-title":"Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?","volume":"13","author":"Murrell","year":"2018","journal-title":"Radiation Oncology"},{"key":"2024050310481576800_b14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040885","article-title":"Stereotactic radiotherapy for ultra-central lung oligometastases in non-small-cell lung cancer","volume":"12","author":"Loi","year":"2020","journal-title":"Cancers"},{"key":"2024050310481576800_b15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/1759-7714.13335","article-title":"Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Thorac Cancer"},{"key":"2024050310481576800_b16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"2024050310481576800_b17","article-title":"LungTech, an EORTC phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective","volume":"88","author":"Adebahr","year":"2015","journal-title":"Br J Radiol"},{"key":"2024050310481576800_b18","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.prro.2018.11.005","article-title":"Tumor control and toxicity after SBRT for ultracentral, central, and paramediastinal lung tumors","volume":"9","author":"Nguyen","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"2024050310481576800_b19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thorac Cancer"},{"key":"2024050310481576800_b20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2019.0205","article-title":"Analysis of toxic effects with antiangiogenic agents plus stereotactic body radiation in Ultracentral lung tumors","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2024050310481576800_b21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2020.07.009","article-title":"Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors","volume":"147","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"key":"2024050310481576800_b22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00066-018-01419-0","article-title":"Stereotactic body radiotherapy of central lung malignancies using a\u00a0simultaneous integrated protection approach","volume":"195","author":"Mazzola","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"2024050310481576800_b23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2019.08.059","article-title":"Predicting high-grade esophagus toxicity after treating central lung tumors with stereotactic radiation therapy using a normal tissue complication probability model","volume":"106","author":"Duijm","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050310481576800_b24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1748-717X-7-152","article-title":"Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer","volume":"7","author":"Chang","year":"2012","journal-title":"Radiat Oncol"},{"key":"2024050310481576800_b25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3109\/0284186X.2013.831185","article-title":"Is there an impact of heart exposure on the incidence of radiation pneumonitis? analysis of data from a large clinical cohort","volume":"53","author":"Tucker","year":"2014","journal-title":"Acta Oncol"},{"key":"2024050310481576800_b26","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/j.cllc.2017.08.002","article-title":"Survival impact of cardiac dose following lung stereotactic body radiotherapy","volume":"19","author":"Wong","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2024050310481576800_b27","doi-asserted-by":"crossref","first-page":"18135","DOI":"10.18632\/oncotarget.7636","article-title":"Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"2024050310481576800_b28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ctrv.2008.06.001","article-title":"Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma","volume":"34","author":"Nguyen","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"2024050310481576800_b29","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2024050310481576800_b30","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2024050310481576800_b31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijrobp.2020.03.005","article-title":"Correlating dose variables with local tumor control in stereotactic body radiation therapy for early-stage non-small cell lung cancer: a modeling study on 1500 individual treatments","volume":"107","author":"Klement","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050310481576800_b32","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer-a safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/95\/1129\/20210533\/57371013\/bjr.20210533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/95\/1129\/20210533\/57371013\/bjr.20210533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T06:49:51Z","timestamp":1714718991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20210533\/7451407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":32,"journal-issue":{"issue":"1129","published-online":{"date-parts":[[2021,11,26]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20210533","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-296037\/v1","asserted-by":"object"}]},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,11,26]]},"article-number":"20210533"}}